Granules India, a provider of pharmaceutical products and services, has received  US FDA  approval for its abbreviated new drug applications.

The company has got approval for its drugs namely Ibuprofen Tablets USP, 400mg, 600 mg and 800 mg.

C Krishna Prasad, chairman and managing director of Granules India, said "It's my pleasure to state that US FDA completed the review of Ibuprofen ANDA filed by us and has given its final approval. It will further strengthen our base business and enable us to increase our product offering to our customers in USA."

Shares of the company gained Rs 0.4, or 0.35%, to settle at Rs 115.40. The total volume of shares traded was 259,718 at the BSE (Wednesday).